GLP-1 receptor agonists: effects on cardiovascular risk reduction
This view suggests that semaglutide captures most of the available benefit from incretin-based therapy, and tirzepatides advantage comes from fine-tuning rather than fundamentally different mechanisms
Patients should contact a clinician if they cannot keep fluids down, have very dark urine, feel faint, or develop persistent vomiting or diarrhea
This stack works by addressing the key factors that often hinder weight loss: constant cravings, a sluggish metabolism, poor gut health, and insufficient sleep
Synergy between Gz deficiency and GLP-1 analog treatment in preserving functional -cell mass in experimental diabetes
Obesity and cancer risk: Emerging biological mechanisms and perspectives